Keterangan
This webinar will cover “Insulin intensification in management of T2DM”. Will explore the discovery of insulin, evaluate the early experiences with insulin and assess the insulin innovation and real world experience. Insulin became the biggest contribution in the area of medical research, which completely transformed the treatment of diabetes by saving millions of lives worldwide. The primary goal of insulin intensification within the primary care setting is to minimize patients exposure to chronic hyperglycemia, weight gain and reduce patients risk of hypoglycemia, while achieving individualized fasting postprandial and A1C targets. Patients with type 2 diabetes need insulin therapy if other treatments haven't been able to keep the blood glucose level within required range and it prevents from other diabetes complications.
Ringkasan
- Dr. Srishi Kanak introduced Dr. Magdi Muhammad Alam, who discussed insulin intensification in managing type 2 diabetes, emphasizing practical applications over academic review. He highlighted the historical significance of insulin's discovery and its evolution over time, referencing key figures like Frederick Banting and Charles Best, along with significant milestones in insulin development.
- The presentation centered on a case study of Mrs. Naga, a 51-year-old with type 2 diabetes, detailing her medical history, current medications, and examination findings. Dr. Alam outlined a five-step approach to managing her diabetes: risk categorization, target setting, glucose control, treatment selection, and regular reassessment. He emphasized individualizing treatment targets based on factors such as hypoglycemia risk, disease duration, and comorbidities.
- Dr. Alam stressed the importance of reaching HbA1c targets to prevent complications, citing the "legacy effect." He discussed different treatment approaches, emphasizing that early insulin introduction should be considered in patients with catabolism, hyperglycemic symptoms, or HbA1c levels above 10%. He noted that insulin can reduce HbA1c levels more effectively than other medicines.
- The presentation explored the selection and titration of basal insulin, recommending long-acting options with lower variability. Dr. Alam outlined titration algorithms, advocating for individualized fasting blood sugar targets. He then presented a second case study, AMA, a 58-year-old with type 2 diabetes, to illustrate the use of GLP-1 receptor agonists in combination with insulin for better glycemic control and weight management.
- Dr. Alam discussed the benefits of combining basal insulin with GLP-1 agonists, noting synergistic effects on HbA1c, fasting and postprandial glucose levels, and weight. He highlighted the importance of discontinuing DPP-4 inhibitors when initiating GLP-1 agonists. He provided guidance on initiating and titrating the combined therapy and emphasized the overall goal of achieving target HbA1c levels while minimizing hypoglycemia and other side effects.
Contoh Sertifikat
Tentang Pembicara
Dr. MAGDY M. ALLAM
DOSEN Penyakit Dalam & Endokrinologi AUSH Konsultan Endokrinologi, Rumah Sakit Zulekha, Dubai Anggota Universitas John Hopkins Anggota Masyarakat Endokrinologi Eropa Anggota Masyarakat Endokrinologi & Obesitas Mesir
Pengungkapan Keuangan
Komentar
Komentar
Anda harus login untuk meninggalkan komentar.